The Report Global Hemophilia Market Report: 2015 Edition provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
Albany, NY -- (SBWIRE) -- 06/01/2015 -- Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.
View Full Report at http://www.marketresearchreports.biz/analysis/281630
The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/281630
The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.
By combining SPSS Inc.'s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Content
2. Market Analysis
2.1 Global Hemophilia Market
2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A
Supply/Demand of Factor VIII
2.2.2 Hemophilia B
2.2.3 Hemophilia A & B with Inhibitors
2.2.4 Von Willebrand Disease
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Read our latest articles at http://www.marketresearchreports.biz/articles
Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
USA: Canada Toll Free: 866-997-4948